{Reference Type}: Journal Article
{Title}: Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations.
{Author}: Casado-Arroyo R;Bernardi M;Sabouret P;Franculli G;Tamargo J;Spadafora L;Lellouche N;Biondi-Zoccai G;Toth PP;Banach M;
{Journal}: Expert Opin Investig Drugs
{Volume}: 0
{Issue}: 0
{Year}: 2024 Aug 8
{Factor}: 6.498
{DOI}: 10.1080/13543784.2024.2388583
{Abstract}: <B>UNASSIGNED: </B>Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. Its prevalence has increased due to worldwide populations that are aging in combination with the growing incidence of risk factors associated. Recent advances in our understanding of AF pathophysiology and the identification of nodal players involved in AF-promoting atrial remodeling highlights potential opportunities for new therapeutic approaches.<BR><B>UNASSIGNED: </B>This detailed review summarizes recent developments in the field antiarrhythmic drugs in the field AF.<BR><B>UNASSIGNED: </B>The current situation is far than optimal. Despite clear unmet needs in drug development in the field of AF treatment, the current development of new drugs is absent. The need for a molecule with absence of cardiac and non-cardiac toxicity in the short and long term is a limitation in the field. Improvement in the understanding of AF genetics, pathophysiology, molecular alterations, big data and artificial intelligence with the objective to provide a personalized AF treatment will be the cornerstone of AF treatment in the coming years.